INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Neurogene Inc. and its officers or directors [1] Group 1: Clinical Trial and Stock Performance - On November 11, 2024, Neurogene reported interim clinical data from its Phase 1/2 trial for NGN-401 gene therapy, which was characterized as "positive," but one patient experienced a serious adverse event [2] - Following the adverse event news, Neurogene's stock price dropped by $31.53, or 44.08%, closing at $40.00 per share on November 12, 2024 [2] - On November 18, 2024, Neurogene updated that the patient was in critical condition and would not complete enrollment in the low-dose cohort as anticipated [3] - This update led to a sharp decline in Neurogene's stock price during intraday trading on November 18, 2024 [3] Group 2: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has a track record of recovering multimillion-dollar damages for class members over its 80-year history [4]